OBJECTIVE: To determine whether history of hypertension, hypercholesterolemia, or diabetes is associated with risk of Parkinson disease (PD). METHODS: Prospective study among participants in two large cohorts: the Nurses' Health Study (121,046 women) and the Health Professionals Follow-up Study (50,833 men). Mean duration of follow-up was 22.9 years in women, aged 30 to 55 years at baseline, and 12.6 years in men, aged 40 to 75 years at baseline. Relative risks (RRs) of PD were estimated from a Cox proportional hazards model adjusting for potential confounders. RESULTS: We identified a total of 530 incident cases of PD during the follow-up. Risk of PD was not associated with self-reported history of hypertension (RR = 0.96, 95% CI = 0.80 to 1.15), high cholesterol (RR = 0.98, 95% CI = 0.82 to 1.19), or diabetes (RR = 1.04, 95% CI = 0.74 to 1.46), after adjusting for age and smoking in pack-years. Risk of PD decreased modestly with increasing levels of self-reported total cholesterol (RR for a 50-mg/dL increase in total cholesterol = 0.86, 95% CI = 0.78 to 0.95, p for trend = 0.02), but use of cholesterol-lowering drugs was not associated with PD risk (RR comparing users with nonusers = 0.85, 95% CI = 0.59 to 1.23). Among individuals with PD, systolic blood pressure was similar to noncases up to the time of diagnosis but declined afterward. CONCLUSIONS: Results of this large prospective study suggest that Parkinson disease risk is not significantly related to history of hypertension, hypercholesterolemia, or diabetes but may modestly decline with increasing blood cholesterol levels.
OBJECTIVE: To determine whether history of hypertension, hypercholesterolemia, or diabetes is associated with risk of Parkinson disease (PD). METHODS: Prospective study among participants in two large cohorts: the Nurses' Health Study (121,046 women) and the Health Professionals Follow-up Study (50,833 men). Mean duration of follow-up was 22.9 years in women, aged 30 to 55 years at baseline, and 12.6 years in men, aged 40 to 75 years at baseline. Relative risks (RRs) of PD were estimated from a Cox proportional hazards model adjusting for potential confounders. RESULTS: We identified a total of 530 incident cases of PD during the follow-up. Risk of PD was not associated with self-reported history of hypertension (RR = 0.96, 95% CI = 0.80 to 1.15), high cholesterol (RR = 0.98, 95% CI = 0.82 to 1.19), or diabetes (RR = 1.04, 95% CI = 0.74 to 1.46), after adjusting for age and smoking in pack-years. Risk of PD decreased modestly with increasing levels of self-reported total cholesterol (RR for a 50-mg/dL increase in total cholesterol = 0.86, 95% CI = 0.78 to 0.95, p for trend = 0.02), but use of cholesterol-lowering drugs was not associated with PD risk (RR comparing users with nonusers = 0.85, 95% CI = 0.59 to 1.23). Among individuals with PD, systolic blood pressure was similar to noncases up to the time of diagnosis but declined afterward. CONCLUSIONS: Results of this large prospective study suggest that Parkinson disease risk is not significantly related to history of hypertension, hypercholesterolemia, or diabetes but may modestly decline with increasing blood cholesterol levels.
Authors: M Kivipelto; E L Helkala; M P Laakso; T Hänninen; M Hallikainen; K Alhainen; H Soininen; J Tuomilehto; A Nissinen Journal: BMJ Date: 2001-06-16
Authors: E-K Tan; C Tan; S M C Fook-Chong; S Y Lum; A Chai; H Chung; H Shen; Y Zhao; M L Teoh; Y Yih; R Pavanni; V R Chandran; M C Wong Journal: J Neurol Sci Date: 2003-12-15 Impact factor: 3.181
Authors: Karen M Powers; Terri Smith-Weller; Gary M Franklin; W T Longstreth; Phillip D Swanson; Harvey Checkoway Journal: Parkinsonism Relat Disord Date: 2008-04-18 Impact factor: 4.891
Authors: Benjamin R Kummer; Iván Diaz; Xian Wu; Ashley E Aaroe; Monica L Chen; Costantino Iadecola; Hooman Kamel; Babak B Navi Journal: Ann Neurol Date: 2019-08-29 Impact factor: 10.422
Authors: Michel M Joosten; Jennifer K Pai; Monica L Bertoia; Eric B Rimm; Donna Spiegelman; Murray A Mittleman; Kenneth J Mukamal Journal: JAMA Date: 2012-10-24 Impact factor: 56.272
Authors: Sonia Franciosi; Miguel A Gama Sosa; Daniel F English; Elizabeth Oler; Twethida Oung; William Gm Janssen; Rita De Gasperi; James Schmeidler; Dara L Dickstein; Christoph Schmitz; Sam Gandy; Patrick R Hof; Joseph D Buxbaum; Gregory A Elder Journal: Mol Neurodegener Date: 2009-10-24 Impact factor: 14.195